Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RGNT
RGNT logo

RGNT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Regentis Biomaterials Ltd (RGNT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
2.410
1 Day change
88.28%
52 Week Range
8.350
Analysis Updated At
2026/06/05
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

RGNT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is in a weak pre-market downtrend, lacks supportive news or catalyst flow, has no bullish proprietary trading signal, and the technical setup is bearish. Based on the available data, the better call is to avoid buying now and wait for a clearer turnaround.

Technical Analysis

Technically, RGNT looks weak. The stock is down 12.79% in pre-market to 1.5, which is below the key pivot level of 2.02 and even under S1 at 1.607, indicating downside pressure. The MACD histogram is negative at -0.0046 and still contracting, showing bearish momentum. RSI_6 at 34.201 is near oversold but not yet a strong reversal signal. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which confirms a downtrend. The short-term pattern model suggests only modest near-term upside probabilities, but that is not enough to offset the current weak structure.

Positive Catalysts

  • No news in the recent week. The only mild positive is the pattern-based projection showing a 24.33% chance of improvement over the next month, but this is not a confirmed catalyst. There are no bullish insider, hedge fund, or proprietary trading signals to support a buy.

Neutral/Negative Catalysts

  • Pre-market price is sharply down 12.79%. Hedge funds are neutral and insiders are neutral, so there is no accumulation signal. No recent news means no event-driven upside catalyst. AI Stock Picker shows no signal today, and SwingMax shows no recent signal. Technical trend remains bearish with negative MACD and bearish moving averages. Congress trading data is unavailable, so there is no supportive political buying signal.

Financial Performance

Latest quarter financials are not available because the financial snapshot returned an error. As a result, there is no readable latest-quarter season or growth trend data to support a fundamental buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible Wall Street upgrade/downgrade trend to support the stock. Based on the available information, Wall Street pros would currently lean cautious to negative because there is no evidence of improving fundamentals, no recent news catalyst, and the technical setup remains weak.

Wall Street analysts forecast RGNT stock price to rise
Analyst Rating
0
Wall Street analysts forecast RGNT stock price to rise
Buy
Hold
Sell
0
Current: 1.280
sliders
Low
0
Averages
0
High
0
0
Current: 1.280
sliders
Low
0
Averages
0
High
0
ThinkEquity
initiated
$10
AI Analysis
2026-03-02
Reason
ThinkEquity
Price Target
$10
AI Analysis
2026-03-02
initiated
Reason
ThinkEquity initiated coverage of Regentis Biomaterials with a Buy rating and $10 price target. Regentis is a single-asset medtech company advancing GelrinC for focal knee cartilage defects, the analyst tells investors in a research note. The firm says "de-risking is underway."

People Also Watch